Andamertinib clinical trials
Also written PLB1004.
How each study uses andamertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the andamertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 1
Avistone Biotechnology Co., Ltd. (8) · Fudan University (1) · Beijing Pearl Biotechnology Limited Liability Company (1) · Avistone Pharmaceutical(Ningbo)Co., LTD. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test andamertinib.
- Nov 2026Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsPhase 2 · Avistone Biotechnology Co., Ltd.
- Dec 2026Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIPhase 1/2 · Avistone Biotechnology Co., Ltd.
Studies
Open first, then newest update. How each study uses andamertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveRecruitingPhase 1/2Avistone Pharmaceutical(Ningbo)Co., LTD.NCT07063329Written as PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy
- The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Fudan UniversityNCT07780578Written as Andamertinib
- Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.Enrolling by invitationPhase 3Avistone Biotechnology Co., Ltd.NCT06281964Written as PLB1004
- Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsRecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT07336732Written as PLB1004
- A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNot yet recruitingPhase 1/2Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148Written as ANS014004 + PLB1004
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNot yet recruitingPhase 3Avistone Biotechnology Co., Ltd.NCT06970782Written as PLB1004
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIRecruitingPhase 1/2Avistone Biotechnology Co., Ltd.NCT06343064Written as PLB1004
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.RecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06574347Written as PLB1004
- A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerRecruitingPhase 1Avistone Biotechnology Co., Ltd.NCT06046495Written as PLB1004
- A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)Active, not recruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06015503Written as PLB1004
- Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 1Avistone Biotechnology Co., Ltd.NCT05347628Written as PLB1004
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call andamertinib · ClinicalTrials.gg INT015142
- UNII (FDA) 5X3KAG7ZBWANDAMERTINIBOne source FDA
- NCI Thesaurus C209347AndamertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5X3KAG7ZBW | ANDAMERTINIB | One source FDA |
| NCI Thesaurus | C209347 | Andamertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.